← Back to Analyst Consensus 
PMN Buy
ProMIS Neurosciences Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 14, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 29, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 28, 2026 | Chardan Capital | maintain | Buy → Buy | — | 46% |
| Jul 27, 2026 | Chardan Capital | initiate | — → Buy | — | 46% |
| Jul 8, 2026 | Roth Capital | initiate | — → Buy | — | 52% |
| Jun 30, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Jun 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 6, 2026 | Guggenheim | maintain | Buy → Buy | $35 | 52% |
| Dec 1, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Nov 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $4 | 44% |
| Nov 18, 2025 | Guggenheim | maintain | Buy → Buy | $5 | 52% |
| Jul 14, 2025 | HC Wainwright & Co. | initiate | — → Buy | $4 | 44% |
| May 12, 2025 | Maxim Group | initiate | — → Buy | $3 | 41% |
| Apr 1, 2025 | Guggenheim | reiterate | Buy → Buy | $6 | 52% |
| Feb 26, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
Price Target Trend
Apr 3, 2026 Latest: $43.4 Oct 25, 2026
EPS Estimates
+1q $-1.95
Lo: $-2.05 Hi: $-1.86
2 analysts +1y $-5.48
Lo: $-9.48 Hi: $-3.44
8 analysts ▲1
0y $-7.36
Lo: $-7.49 Hi: $-7.23
2 analysts 0q $-1.82
Lo: $-1.85 Hi: $-1.79
2 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days